Australian Regulator On The Highs & Lows Of Project Orbis

 
• By Ian Schofield

The US FDA-led initiative for collaborative submission and review of new cancer drugs has produced a number of benefits since it was introduced in 2019, including more “robust” regulatory decisions and earlier market access, the DIA Europe 2022 conference heard. 

Train_Track
Project Orbis uses concurrent reviews to speed new cancer drugs to market • Source: Shutterstock

More from International

More from Geography